Pharmacodynamics of insulin in polyethylene glycol-coated liposomes

被引:48
作者
Kim, A
Yun, MO
Oh, YK
Ahn, WS
Kim, CK
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Catholic Univ Korea, Coll Med, Seoul 137140, South Korea
关键词
incorporation; insulin; liposomes; pharmacodynamics; polyethylene glycol;
D O I
10.1016/S0378-5173(98)00408-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To reduce the injection frequency and toxicity of intravenously administered protein drugs, it is necessary to develop safe and sustained injectable delivery systems. In this study, to evaluate liposomes as safe and sustained injectable delivery systems of proteins. we chose insulin as a modal protein drug and tested its incorporation efficiency and pharmacodynamics in various liposomes with and without polyethylene glycol (PEG)-derivatized phospholipid. The liposomes coated with PEG showed 3-fold higher efficiency of insulin incorporation than did the liposomes without PEG. Moreover, among the liposomes coated with PEG, dipalmitoylphosphocholine (DPPC) liposomes showed higher incorporation efficiency than did dimyristoylphosphocholine (DMPC) liposomes. For pharmacodynamic study, insulin (2 IU/kg) was administered in various formulations, such as insulin alone in phosphate-buffered saline and insulin in the DPPC liposomes with and without PEG, to streptozotocin-treated diabetic rats. The pharmacodynamics of insulin alone, however, could not be measured due to the immediate death of rats caused by hypoglycemic shock. In contrast, all the rats treated with liposomal insulin survived, probably by the sustained release of insulin from liposomes. Pharmacodynamics of liposomal insulin showed that PEG-coated liposomes induced the lowest level of blood glucose-the nadir-1 h later than did the liposomes without PEG. These results indicate that PEG-coated liposomes could be developed as a relatively safe and sustained injectable delivery system for insulin with improved incorporation efficiency. Moreover, it is suggested that the liposomes coated with PEG might have a potential as safe injectable delivery systems for other protein and peptide drugs. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 13 条
[1]   LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :91-97
[2]   LIPOSOMES AND NANOPARTICLES IN THE TREATMENT OF INTRACELLULAR BACTERIAL-INFECTIONS [J].
COUVREUR, P ;
FATTAL, E ;
ANDREMONT, A .
PHARMACEUTICAL RESEARCH, 1991, 8 (09) :1079-1086
[3]  
DEBS RJ, 1990, CANCER RES, V50, P375
[4]   Polyethylene glycol coated (pegylated) liposomal doxorubicin - Rationale for use in solid tumours [J].
Gabizon, A ;
Martin, F .
DRUGS, 1997, 54 (Suppl 4) :15-21
[5]   PROLONGATION OF THE CIRCULATION TIME OF DOXORUBICIN ENCAPSULATED IN LIPOSOMES CONTAINING A POLYETHYLENE GLYCOL-DERIVATIZED PHOSPHOLIPID - PHARMACOKINETIC STUDIES IN RODENTS AND DOGS [J].
GABIZON, AA ;
BARENHOLZ, Y ;
BIALER, M .
PHARMACEUTICAL RESEARCH, 1993, 10 (05) :703-708
[6]   DEVELOPMENT OF DRIED LIPOSOME AS EFFECTIVE IMMUNO-ADJUVANT FOR HEPATITIS-B SURFACE-ANTIGEN [J].
KIM, CK ;
JEONG, EJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 115 (02) :193-199
[7]   LYMPHATIC DELIVERY AND PHARMACOKINETICS OF METHOTREXATE AFTER INTRAMUSCULAR INJECTION OF DIFFERENTLY CHARGED LIPOSOME-ENTRAPPED METHOTREXATE TO RATS [J].
KIM, CK ;
HAN, JH .
JOURNAL OF MICROENCAPSULATION, 1995, 12 (04) :437-446
[8]  
KIM CK, 1994, INT J PHARM, V101, P191
[9]   STERICALLY STABILIZED LIPOSOMES - A HYPOTHESIS ON THE MOLECULAR-ORIGIN OF THE EXTENDED CIRCULATION TIMES [J].
LASIC, DD ;
MARTIN, FJ ;
GABIZON, A ;
HUANG, SK ;
PAPAHADJOPOULOS, D .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1070 (01) :187-192
[10]  
OWENS DR, 1986, HUMAN INSULIN CLIN P, P98